Health Blueprint

Back to Longevity News

News summary

Traded: Venture Capital 🦄 on Instagram: "Peter Diamandis and Yianni Psaltis launched NeoGenesis Capital and announced the initial closing of its first fund, with Oliver Trevena joining as Head of Culture. The firm invests in Colossal Biosciences and in the companies built on and spun out of Colossal’s platform, driving breakthroughs in longevity, fertility, agriculture, environmental remediation, AI-native genetic design, and more. Initial investments include: •⁠ ⁠Colossal Biosciences: Led by CEO Ben Lamm, developing a platform for programmable biology and launching companies from its ecosystem. •⁠ ⁠Breaking: Applying synthetic biology to plastic degradation. •⁠ ⁠Astromech: Building predictive AI for biology. The thesis is simple: biology is becoming programmable. As superintelligence and synthetic biology converge, a new generation of living products, companies, and industries is emerging. Learn more: neogenesiscapital.com #NeoGenesisCapital #PeterDiamandis #YianniPsaltis #OliverTrevena #TradedVC"

Source: traderVC • Published: 15 Oct 2026, 21:25

Summarized by Masters of Longevity from traderVC.

A quick-read post about a new venture firm focused on programmable biology and the types of synthetic-biology startups it plans to back.

Traded: Venture Capital 🦄 on Instagram: "Peter Diamandis and Yianni Psaltis launched NeoGenesis Capital and announced the initial closing of its first fund, with Oliver Trevena joining as Head of Culture. The firm invests in Colossal Biosciences and in the companies built on and spun out of Colossal’s platform, driving breakthroughs in longevity, fertility, agriculture, environmental remediation, AI-native genetic design, and more. Initial investments include: •⁠ ⁠Colossal Biosciences: Led by CEO Ben Lamm, developing a platform for programmable biology and launching companies from its ecosystem. •⁠ ⁠Breaking: Applying synthetic biology to plastic degradation. •⁠ ⁠Astromech: Building predictive AI for biology. The thesis is simple: biology is becoming programmable. As superintelligence and synthetic biology converge, a new generation of living products, companies, and industries is emerging. Learn more: neogenesiscapital.com #NeoGenesisCapital #PeterDiamandis #YianniPsaltis #OliverTrevena #TradedVC"
Key Takeaways
  • NeoGenesis Capital launched with an initial fund close and a leadership team including Peter Diamandis and Yianni Psaltis.
  • Initial portfolio positions mentioned are Colossal Biosciences, Breaking, and Astromech as early investments.
Read the full article at traderVC ↗

Continue exploring

Recommended MoL Picks

MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.